|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| ctDNA Fraction Predicts Response to Lutetium PSMA in TheraP Trial for mCRPC |
Edmond Kwan, MBBS, PhD
Edmond Kwan discusses his latest research on circulating tumor DNA (ctDNA) as a predictive marker for response to Lutetium PSMA-617 versus cabazitaxel. The Phase II TheraP trial compared these treatments in patients with advanced metastatic castration-resistant prostate cancer, utilizing dual imaging selection. |
|
|
|
|
|
|
|
|
|
|
| Genomic Alterations and Lutetium PSMA Response in Prostate Cancer |
Alexandra Sokolova, MD
Alexandra Sokolova discusses her team's study on genomic alterations influencing the response to lutetium-177 PSMA in metastatic castration-resistant prostate cancer. Their research highlights the need for better biomarkers to predict patient outcomes with lutetium-177 PSMA, as not all patients respond to this treatment. |
|
|
|
|
|
|
|
|
|
|
| SECuRE Trial: Copper-67 PSMA Therapy for Prostate Cancer |
| Geoffrey Johnson, MD, PhD |
| Zach Klaassen and Geoffrey Johnson discuss the SECuRE trial, a phase 1-2 dose escalation expansion study of a PSMA-targeted radiopharmaceutical for prostate cancer using copper 67. This innovative therapy boasts a unique chelator, enhancing drug delivery and reducing systemic leakage. |
|
|
|
|
|
|
|
|
|
|
|
| ctDNA Fraction as a Predictor of Treatment Efficacy in a Randomized Phase 2 Trial of [177Lu] Lu-PSMA-617 Versus Cabazitaxel in mCRPC Progressing After Docetaxel
|
| Edmond Michael Kwan, PhD, MBBS, FRACP
|
| Edmond Kwan discusses using ctDNA fraction as a predictor in a phase 2 trial comparing [177Lu] Lu-PSMA-617 and cabazitaxel for metastatic castration-resistant prostate cancer after docetaxel failure. The study found that lower ctDNA levels were associated with significantly higher PSA response rates and longer progression-free survival with Lu-PSMA compared to cabazitaxel.
|
|
|
|
|
|
| SECuRE: A Dose Escalation/Expansion Study to Assess the Anti-Tumor Efficacy of 67Cu-SAR-bisPSMA in Patients with Metastatic Castrate Resistant Prostate Cancer
|
| Geoffrey Johnson, MD, PhD
|
| Geoffrey Johnson presents SECuRE at ASCO 2024, a phase I/IIa study evaluating the safety and anti-tumor efficacy of 67Cu-SAR-bisPSMA in metastatic castrate-resistant prostate cancer. The study builds on preclinical evidence showing promising tumor growth inhibition with this dual PSMA-targeting agent.
|
|
|
|
|
|
|
|
|
|
|
| Combination Treatment of Prostate Cancer Using Pembrolizumab with PSMA-Based Radioligands |
| Thomas Hope, MD |
| Thomas Hope presents findings at SNMMI 2024 on combining pembrolizumab with PSMA-based radioligand therapy in prostate cancer. Highlighting immune checkpoint inhibitors' role in enhancing T-cell activation, he discussed the PRINCE and UCSF trials, demonstrating promising efficacy with manageable toxicity profiles. The studies aimed to optimize treatment by leveraging radioligand therapy's potential to prime the immune system, setting the stage for ongoing trials to explore further enhancements in therapeutic outcomes. |
|
|
|
|
|
| PSMA Radioligands: Current and Future
|
| Scott T. Tagawa, MD, MS, FACP, FASCO
|
| Scott Tagawa discusses the current and future applications of PSMA-targeted radionuclide therapy. This therapy involves systemic administration of radioisotopes that target PSMA-expressing cells, using agents like 177Lu-PSMA-617 and 225Ac-PSMA-617. Clinical trials such as TheraP and VISION have shown promising results, demonstrating improvements in PSA progression-free survival and overall survival in mCRPC patients.
|
|
|
|
|
|
| Efficacy and Safety of 177Lu-PNT2002 Prostate-Specific Membrane Antigen (PSMA) Therapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Initial Results from SPLASH |
| Aaron R. Hansen, MD |
| Aaron Hansen presented initial findings from the SPLASH trial at ESMO 2022, evaluating 177Lu-PNT2002 in PSMA-positive metastatic castration-resistant prostate cancer patients who progressed after androgen receptor axis-targeted therapy. Adverse events were manageable, with common grade ≥3 events including anemia and hematuria. These results support the ongoing randomized phase of the SPLASH trial. |
|
|
|
|
|
| Final Results of a Phase I/II Dose-Escalation Study of Fractionated Dose 177Lu-PSMA-617 for Progressive mCRPC
|
| Scott Tagawa, MD, MS, FACP, FASCO
|
| Scott Tagawa presents the final results from a phase I/II study on fractionated dose 177Lu-PSMA-617 for progressive mCRPC. The study demonstrated safety up to 22.2 GBq in a single cycle with fractionated dosing, yielding significant PSA declines and favorable radiographic progression-free survival and overall survival compared to historical controls.
|
|
|
|
|
|
